Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 9/20 | 0.55 |
| ▸ | PNP | P00491 | 3/20 | 0.34 |
| ▸ | BLM | P54132 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | PAH | P00439 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL10601101 | 0.99 | HPRT1 (0.54) | HPRT1PNPBLMALDH1A1KMT2A | |
| Ammonia Solution, Strong SCHEMBL10901621 | 0.99 | HPRT1 (0.54) | HPRT1PNPBLMALDH1A1KMT2A | |
| Phosphoric Acid SCHEMBL9471917 | 0.96 | HPRT1 (0.59) | HPRT1PNPBLMALDH1A1KMT2A | |
| SCHEMBL60630 | 0.91 | HPRT1 (0.57) | HPRT1BLMALDH1A1KMT2AMEN1 | |
| SCHEMBL147641 | 0.84 | HPRT1 (0.67) | HPRT1PNPBLMALDH1A1KMT2A | |
| SCHEMBL2775722 | 0.84 | HPRT1 (0.55) | HPRT1BLMALDH1A1KMT2AMEN1 | |
| SCHEMBL7132437 | 0.83 | HPRT1 (0.60) | HPRT1PNPBLMALDH1A1KMT2A | |
| Ganciclovir SCHEMBL8689225 | 0.83 | BLM (0.65) | HPRT1PNPBLMALDH1A1KMT2A | |
| SCHEMBL10970955 | 0.82 | HPRT1 (0.47) | HPRT1PNPBLMALDH1A1KMT2A | |
| SCHEMBL10919055 | 0.82 | HPRT1 (0.58) | HPRT1PNPBLMALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2851368-B1 | COMPLEX COMPOUNDS OF GERMANIUM, METHODS FOR PRODUCING SAME, AND DRUGS | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU WDS FARMA (RU) | 2019-01-02 | — | — | EP | claimed |
| US-9745337-B2 | Complex compounds of germanium, methods for producing same, and drugs | OBSCHESNO S OGRANICHENNOI OTVETSTVENNOSTYU “WDS FARMA” (RU) | 2017-08-29 | — | — | US | claimed |
| US-20150126726-A1 | COMPLEX COMPOUNDS OF GERMANIUM, METHODS FOR PRODUCING SAME, AND DRUGS | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "WDS FARMA" (RU) | 2015-05-07 | — | — | US | claimed |
| EP-2851368-A1 | COMPLEX COMPOUNDS OF GERMANIUM, METHODS FOR PRODUCING SAME, AND DRUGS | Obschestvo S Ogranichennoi Otvetstvennostyu "WDS FARMA" (RU) | 2015-03-25 | — | — | EP | claimed |
| CN-104302651-A | Germanium complex, process for producing the same and pharmaceutical | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU WDS FARMA | 2015-01-21 | — | — | CN | claimed |
| EP-1146881-B1 | PREPARATION FOR THE PREVENTION AND/OR TREATMENT OF A TISSUE CHANGE OF MESENCHYMAL ORIGIN | BULLERDIEK JOERN (DE) | 2006-01-04 | — | — | EP | claimed |
| US-20020147175-A1 | Synergistic ECTA compositions | NEWBIOTICS, INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002069949-A2 | COMBINATION THERAPY FOR REDUCTION OF TOXYCITY OF CHEMOTHERAPEUTIC AGENTS | PRENDERGAST PATRICK T (IE) | 2002-09-12 | — | — | WO | claimed |
| WO-2002039952-A2 | SYNERGISTIC ECTA COMPOSITIONS | NEWBIOTICS, INC. (US) | 2002-05-23 | — | — | WO | claimed |
| US-6015573-A | TREATMENT OF RESISTANT HERPES VIRUS WITH NUCLEOSIDE PHOSPHATE ESTERS | RESOLUTION PERFORMANCE PRODUCTS LLC | 2000-01-18 | — | — | US | claimed |
| US-5879700-A | TREATING HERPES VIRUS INFECTIONS | HOSTETLER KARL Y (US) | 1999-03-09 | — | — | US | claimed |
| EP-0746319-A4 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1997-11-05 | — | — | EP | claimed |
| US-5648489-A | PREPARING 9-((1,3-DIHYDROXY-2-PROPOXY)METHYL)GUANINE FROM A PROTECTED GUANINE AND 2-ACETOXYMETHOXY-1,3-DIACETOXYPROPANE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 1997-07-15 | — | — | US | claimed |
| EP-0746319-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER, Karl Y. (US) | 1996-12-11 | — | — | EP | claimed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | claimed |
| US-5336770-A | Transglycosilation process for producing acyclic nucleosides | AJINOMOTO CO., INC. (JP) | 1994-08-09 | — | — | US | claimed |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| US-4565868-A | PHOSPHORYLATION, ESTERIFICATION TO PRODUCE PHOSPHATE ESTERS | SYNTEX (U.S.A.) INC. (US) | 1986-01-21 | — | — | US | disclosed |
| EP-0138656-A1 | Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides, their preparation and their application in anti-viral compositions | MERCK & CO. INC. (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147175-A1 | Synergistic ECTA compositions | ENTPD1, ENTPD2, ENPP1 | HPRT1 380/4885PNP 45/4885BLM 1208/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | HPRT1 17/4885PNP 3/4885BLM 4565/4885 |
| US-20150126726-A1 | COMPLEX COMPOUNDS OF GERMANIUM, METHODS FOR PRODUCING SAME, AND DRUGS | GDA, ATIC, AGXT | HPRT1 96/4885PNP 65/4885BLM 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.